Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients - a prospective, randomized, double-blind, phase III trial by Hoffmann, Katrin et al.
Hoffmann et al. BMC Cancer  (2015) 15:392 
DOI 10.1186/s12885-015-1373-zRESEARCH ARTICLE Open AccessImpact of neo-adjuvant Sorafenib treatment on
liver transplantation in HCC patients - a
prospective, randomized, double-blind,
phase III trial
Katrin Hoffmann1, Tom Ganten2, Daniel Gotthardtp2, Boris Radeleff3, Utz Settmacher4, Otto Kollmar5,
Silvio Nadalin6, Irini Karapanagiotou-Schenkel7, Christof von Kalle7, Dirk Jäger7, Markus W Büchler1
and Peter Schemmer1,8*Abstract
Background: Liver Transplantation (LT) is treatment of choice for patients with hepatocellular carcinoma (HCC) within
MILAN Criteria. Tumour progression and subsequent dropout from waiting list have significant impact on the survival.
Transarterial chemoembolization (TACE) controls tumour growth in the treated HCC nodule, however, the risk of
tumour development in the untreated liver is increased by simultaneous release of neo-angiogenic factors. Due
to its anti-angiogenic effects, Sorafenib delays the progression of HCC. Aim of this study was to determine whether
combination of TACE and Sorafenib improves tumour control in HCC patients on waiting list for LT.
Methods: Fifty patients were randomly assigned on a 1:1 ratio in double-blinded fashion at four centers in Germany
and treated with TACE plus either Sorafenib (n = 24) or placebo (n = 26). The end of treatment was development of
progressive disease according to mRECIST criteria or LT. The primary endpoint of the trial was the Time-to-Progression
(TTP). Other efficacy endpoints were Tumour Response, Progression-free Survival (PFS), and Time-to-LT (TTLT).
Results: The median time of treatment was 125 days with Sorafenib and 171 days with the placebo. Fourteen patients
(seven from each group) developed tumour progression during the course of the study period. The Hazard Ratio of TTP
was 1.106 (95% CI: 0.387, 3.162). The results of the Objective Response Rate, Disease Control Rate, PFS, and TTLT were
comparable in both groups. The incidence of AEs was comparable in the placebo group (n = 23, 92%) and in the Sorafenib
group (n = 23, 96%). Twelve patients (50%) on Sorafenib and four patients (16%) on placebo experienced severe
treatment-related AEs.
Conclusion: The TTP is similar after neo-adjuvant treatment with TACE and Sorafenib before LT compared to TACE and
placebo. The Tumour Response, PFS, and TTLT were comparable. The safety profile of the Sorafenib group was similar
to that of the placebo group.
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The age-adjusted incidence of hepatocellular carcinoma
(HCC) has increased continuously over the past twenty
years, making HCC to become one of the fastest growing
causes of cancer-related deaths in the United States and
Europe [1]. The implementation of effective surveillance
programs for patients with Hepatitis B and C infection
has significantly augmented the proportion of patients
who are diagnosed at an early stage of the disease. Cur-
rently, 30-40% of patients are amenable to curative treat-
ment options and the numbers are expected to increase to
60% within the coming decade [2]. Liver Transplantation
(LT) is the only therapy that simultaneously cures the
tumour and the underlying liver disease and the MILAN
Criteria remains the benchmark for patient selection.
Five-year survival rates of 60-70% have been achieved in
high-volume centres with well-selected patients [3,4].
Unfortunately, there remains a great disparity between
organ availability and demand; of all the patients on the
waiting list for LT, less than one third actually undergo
liver transplantations, while most of the enlisted patients
simply drop out due to tumour progression [5]. Progres-
sion of the disease during the waiting time is associated
with poorer transplant outcome [6]. Furthermore, the
remaining, viable tumour in the explanted liver has been
identified a risk factor for disease recurrence [7]. Although
locoregional bridging therapies such as transarterial che-
moembolization (TACE) are known to improve the sur-
vival rates of HCC candidates awaiting LT, their impact on
tumour progression and dropout risk is still uncertain [8].
Complete response is seldom achieved via TACE and the
presence of residual vital tumour is extremely difficult to
evaluate. Nevertheless, locoregional therapies are recom-
mended for bridging before LT [9]. Angiogenic factors are
known to be released after locoregional therapy treatment
and are believed to trigger tumour growth in untreated
livers [10]. However, it might be possible to reduce these
effects by using a treatment combination with an anti-
angiogenic agent.
The oral multi-kinase inhibitor, Sorafenib, has shown
significant efficacy in prolonging the Time-to-Progression
for tumours in two large, Phase III trials and is the stand-
ard treatment for patients with advanced HCC [11,12].
Unfortunately, data on the use of Sorafenib in a neo-
adjuvant setting before liver transplantation are rare [13].
In a Monte Carlo probabilistic sensitivity analysis, Vitale
et al. showed that a neo-adjuvant therapy with Sorafenib
before LT may have beneficial effects on the survival rates
[14]. The strategy of using combined locoregional and
anti-angiogenic therapies has been proven in in vivo cases.
Xu et al. showed that the administration of Sorafenib in
conjunction with radiofrequency ablation reduced the
VEGF and HIF-1α levels, decreased micro-vessel density,
and inhibited tumour growth [15]. However, based on theexperience with other VEGF-targeted therapies in a peri-
operative setting, concerns have been raised regarding the
anti-angiogenic effect of Sorafenib [16]. Reports on the
risk of post-transplantation complications are sparse and
heterogenic [17,18]. Furthermore, it has been speculated
that the toxic effects of Sorafenib may be prevalent in the
presence of vascular and biliary anastomoses, and might
increase the risk of leakage or thrombosis [14,17].
To test the hypothesis of the beneficial effects of a com-
bined locoregional and VEGF-targeted therapy on tumour
progression before LT, we initiated a prospective, multi-
centre, placebo-controlled, randomized, double-blind trial
that investigates the neo-adjuvant treatment course with
TACE and Sorafenib in HCC patients awaiting LT who
have been categorized according to the MILAN criteria
[19]. Here, we report the results of fifty patients treated in
this trial and demonstrate that the Time-to-Progression
while on waiting list is independent of Sorafenib treatment.
Methods
Eligibility criteria
This multi-centre, randomized, placebo-controlled, double-
blind, Phase III trial was performed in four centres in
Germany [19]. The study was approved by the review
boards and independent ethics committees of the partici-
pating institutions (EudraCT-Nr.: 2008-002269-29, ethics
committee of Ruprecht-Karls-University Heidelberg, Med-
ical Faculty Friedrich-Schiller-University Jena, University
Medicine Göttingen and Medical Faculty Eberhard-Karls-
University Tübingen). The trial was done in accordance
with the International Conference on Harmonization
Good Clinical Practice Guidelines, the Declaration of
Helsinki, and the applicable local regulatory requirements
and laws [20].
Patients over 18 years of age who had been diagnosed
with hepatocellular carcinoma according to the MILAN
Criteria were eligible, provided that they were diagnosed
according to the guidelines of the European Association
for the Study of Liver Disease (EASLD) and were found to
be suitable for liver transplantation. All patients had meas-
urable disease parameters that had been classified accord-
ing to mRECIST (modified Response Evaluation Criteria
in Solid Tumours) with no evidence of radiologically de-
finable major vascular invasion or extrahepatic metastases,
a Karnofsky index greater than 80%, adequate liver func-
tion with bilirubin content of <3 mg/dl, a prothrombin
time that was less than 1.5 times higher than the upper
limit of the normal range, and adequate renal and haem-
atological function, as well as, a negative pregnancy test .
All patients provided written informed consent.
The exclusion criteria were: prior systemic, anticancer
therapy or local tumour therapy (i.e. LITT; PEI, cryother-
apy, RFA, TACE), thrombotic or embolic events (including
transient ischemic attacks within six months before study
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within four weeks of first dose of the study drug, any re-
ported cardiovascular disease such as myocardial infarc-
tion six months prior to the start of trial, chronic heart
failure (revised NYHA Grade III-IV) or unstable coronary
artery disease, and uncontrolled hypertension despite opti-
mal medical management. Patients with uncontrolled in-
fections and HIV-seropositive patients were also excluded.
Study treatment and evaluation of adverse events
Patients were treated according to the HeiLivCa study
protocol with either TACE plus Sorafenib (400 mg bid, or-
ally) or TACE plus placebo until progression of disease was
observed or liver transplantation was performed [19,21].
Dose reductions of the study medication were allowed in
patients with clinically significant toxicities. The study
medication was interrupted three days before and contin-
ued three days after each TACE. TACE was performed
using carboplatin as a chemotherapeutic drug and Lipiodol
was used as the embolizing agent, as previously described
[22]. TACE was performed every four weeks until complete
devascularisation of the treated nodule. Computed Tomog-
raphy or Magnetic Resonance Imaging was done four
weeks after each TACE, followed by TACE every eight
weeks until tumour progression or LT. Medical history,
physical examination, assessment of the performance
status, adverse events, and biochemical and haematological
parameters were carried out at baseline of two weeks after
the start of study treatment and then every four weeks dur-
ing the course of the trial. Adverse events were graded
according to the National Cancer Institute Common
Terminology Criteria for Adverse Events (NCI-CTCAE),
Version 3 [23]. LT was performed as previously described
[6]. Routine immuno-suppression included an initial, intra-
operative, induction dose of prednisolone, followed by
CNI-based immunosuppression with cyclosporine A or
tacrolimus with MMF or prednisolone.
Statistical considerations
The primary endpoint of the study was the Time-to-
Progression (TTP) while on the waiting list, assessed by
the mRECIST Criteria. Other efficacy endpoints were
Tumour Response, Progression-free Survival (PFS), and
the Time-to-LT. The ORR (Objective Response Rate) was
defined as either Complete Response (CR) or Partial
Response (PR). Patients with insufficient data for tumour
assessment (e.g., no baseline or follow-up assessments)
were considered as “Not meeting ORR criteria”. DCR
(Disease Control Rate) was defined as CR, PR, or SD
(Stable Disease). TTP was defined as the time between the
first dose of the study medication and the first documen-
tation of tumour progression. For patients with no docu-
mented tumour progression before the study cut-off point
or for those who dropped out of the trial, the CensoringDate was defined as the last date on which the progression
status was adequately assessed. PFS was defined as the
time between the date of the first dose of the study medi-
cation and the date of the first indication of disease pro-
gression or death due to any cause, provided that the
death occurred before tumour progression was docu-
mented. Patients without progression or death were cen-
sored on the date of the last tumour assessment during
the study. The Time-to-LT was defined as the time from
the date of first administration of the study medication to
the date of LT.
The sample size calculation was based on the detection
of significant differences in TTP, assuming that median
TTP was 4.5 months for the placebo-arm and 7.5 months
for the sorafenib-arm (delta of 3 months similar to delta
in SHARP study as presented at ASCO 2007). Presup-
posed exponential survival curves, constant monthly haz-
ard rates, an accrual period of 24 months and a total
follow-up of 33 (=24 + 9) months, and testing for the
above-mentioned difference at an overall one-sided sig-
nificance level of 0.05 and power of 0.875 a total of 136
patients were required. From the experience gained at the
surgery department it was anticipated that about 50% of
the patients will drop-out after randomization. These pa-
tients do not contribute any information to the primary
endpoint. In order to accommodate for a maximum drop-
out rate of 50% the total sample size was therefore in-
creased to 208 (104 per treatment group). Patients were
randomly assigned on a 1:1 ratio in a blinded fashion to
the sorafenib or placebo. A central computer-generated
block-randomized list was prepared by an independent
biostatistician of the KKS in Heidelberg and provided to
the Pharmacy at University Hospital Heidelberg.
According to the study protocol, standard methods for
survival analysis were to be used in the analysis of Time-
to-Event endpoints, including Kaplan-Meier estimates of
the survivor functions, Greenwood’s formula for estimat-
ing the standard error of event rates, the Cox Proportional
Hazards Model, and the log-rank test for comparing sur-
vival curves. However, the HeiLivCa trial was stopped pre-
maturely after the inclusion of fifty patients and, for this
reason, any confirmatory statistical analysis was unattain-
able. Therefore, the statistical analysis actually performed
was in a strictly exploratory and mainly descriptive
manner, and differed from the analyses outlined in the
study protocol. Due to the presence of competing risk fac-
tors in regards to TTP, PFS, and the Time-to-LT, the
Kaplan-Meier estimator could not be used and, therefore,
an analysis of the Competing Risk data was performed
using the SAS macro % Cumulative Incidence Functions
(CIF) [24]. The macro implements used for estimating
Cumulative Incidence Functions in this study were appro-
priate for nonparametric methods. The cumulative inci-
dence for a particular cause of failure is the probability of
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ence of all the other possible causes. The estimates of the
CIF for each treatment group from the aforementioned
Time-to-Event endpoints, the Standard Errors, and the
95% Confidence Intervals were displayed. Additionally,
the test for equality of the CIF among the various treat-
ment groups was performed using Gray’s method [25]. All
data collected in regards to assessing the safety and effi-
cacy of the trial are reported in the summary presenta-
tions, listings, or both. All statistical tests used in the
exploratory analyses were two-tailed. The significance
level was 0.05 and was calculated using SAS Version 9.3.
The end of the study was defined when either the in-
formed consent was withdrawn or the presence of disease
progression or LT was reported.
Evaluation of response
All patients had chest and abdominal imaging (Computed
Tomography using Siemens Somatom Definition and/or
Magnetic Resonance Imaging using Siemens, Symphony,
1.5 t) before the initiation of the Sorafenib therapy. Im-
aging was repeated during the trial as described in the
study protocol to evaluate radiographic response within
the tumour; this response was then classified using the
mRECIST criteria. Densitometric measurement of intra-
tumoural enhancement was performed using a modifica-
tion of the Choi Criteria to evaluate the effect of the
treatment course on tumour viability. Briefly, using axial
source Computed Tomography images (3 mm thickness),
a three-dimensional image of the liver was reconstructed
with an imaging workstation (TeraRecon, USA). The lar-
gest dimensions of the HCC were outlined and a density
measurement in Hounsfield units (HU) was obtained. The
percental change in HU after treatment was recorded.
Role of the sponsor
The study was an investigator-initiated trial (IIT) that was
designed by the principal investigators, Peter Schemmer
and Katrin Hoffmann. All logistical aspects of the study
were managed by the study sponsor, namely, the Univer-
sity of Heidelberg. Data were collected by the study spon-
sor and all authors, and all the aforementioned parties had
full access to the study data. The corresponding author
had the final responsibility of submitting the manuscript
for publication. The study was supported by Bayer Health-
care GmbH, Leverkusen, Germany.
Results
Patients
Of the sixty-seven patients who were screened, a total of
fifty patients were treated within this study. One patient
from the placebo group eventually withdrew the informed
consent. This patient did not receive any study treatment
and, as such, was excluded from the safety analysis. Onthe other hand, all fifty randomized patients were included
in the efficacy analysis. Ten patients withdrew their in-
formed consent (n = 6 from the Sorafenib group and n = 4
from the placebo group) due to compliance issues, two
patients died (one from each group) during the study (one
from a motorcycle accident and the other from general
status impairment), three patients were excluded from
analysis due to protocol violation, and two patients from
the placebo group discontinued participation due to ad-
verse events (a hip fracture and the development of
oesophageal cancer) (Figure 1). The baseline characteris-
tics of the study patients are displayed in Table 1. The me-
dian age of the participants was 58 years (range: 43 to
69 years) and this was representative of 45 males (90.0%)
and 5 female patients (10.0%). A tumour histology ob-
tained by biopsy was available for 14 patients (28.0%). No
patient had metastatic disease and all were found to be
within the MILAN Criteria (Table 1).
Treatment and adverse events
The median number of days on Sorafenib was 125 (range:
1 to 380 days) and the median duration of treatment with
the placebo was 171 (range: 1 to 366 days). TACE was per-
formed in a median number of two in patients of the
Sorafenib group (range: 0 to 4) and three in patients of the
placebo group (range: 2 to 4). No TACE-associated
complications were observed. The majority of the patients
(46 of 50) experienced at least one AE. The incidence of
AEs was slightly lower in the placebo group (92%, 23 of 26
patients) than in the Sorafenib group (96%, 23 of 24
patients). The most frequent, treatment-related AEs were
thrombocytopenia, diarrhea, and hand-foot-skin reactions.
A total of 22 patients (92%) in the Sorafenib group and 21
patients (84%) in the placebo group experienced at least
one treatment-related AE. Twelve patients (50%) on Soraf-
enib and four patients (16%) on the placebo experienced
“Severe” treatment-related adverse events (CTCAE Grade
III or IV), while a total of six patients (three patients from
each group) experienced “serious” treatment-related ad-
verse events (Table 2). Eight patients (n = 2 from the pla-
cebo group and n = 6 from the Sorafenib group) had dose
reductions or temporary discontinuations due to treat-
ment-related adverse events. Seven patients (n = 1 (4.0%)
from the placebo group and n = 6 (25%) from the Sorafe-
nib group) discontinued using the study drug due to treat-
ment-related AE. Even though four patients (two from
each group) died during the observation period, it must be
said that there were no treatment-related deaths in gen-
eral. The safety profile of Child A and Child B patients
was almost similar.
Effect on outcome measures
There were a total of fourteen patients (seven patients from
each group) who experienced tumour progression during
Figure 1 Consort flow diagram.
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(range: 1 to 394 days) in the Sorafenib group and 85 days
(range: 1 to 405 days) in the placebo group. The estimates
of the CIF of TTP, the Standard Errors, and the 95%
Confidence Intervals were similar in the two treatment
groups. The Hazard Ratio was 1.106 (95% CI: 0.387,
3.162) (Figure 2). The PFS was comparable in the both
groups and in this case, the Hazard Ratio was 1.259 (95%
CI: 0.485, 3.270) (Figure 3).
The study ended when there was withdrawal of con-
sent and/or the occurrence of disease progression or LT.
During the last study visit, patients of the Sorafenib group
showed CR (n = 1, 4.3%), PR (n = 4, 17.4%), SD (n = 11,
47.8%), and PD (n = 7, 30.4%) in comparison to patients of
the placebo group CR (n = 0), PR (n = 7, 26.9%), SD (n = 12,
46.2%), and PD (n = 7, 26.9%). The Objective Response
Rate (CR + PR) was 20.8% (95% CI: 7.1 - 42.2) in the
Sorafenib group and 26.9% (95% CI: 11.6 - 47.8) in the
placebo group. The Disease Control Rate (CR + PR + SD)
was 66.7% (95% CI: 44.7 - 84.4) in the Sorafenib group
and 73.1% (95% CI: 52.2 - 88.4) in the placebo group.
Mean change in AFP from baseline to last visit was −76.7
(SD = 267.5, median = −1.9) in the TACE plus Sorafenib
group and 6.5 (SD = 64.2, median = −1.7) in the TACE
plus Placebo group. Considering mean changes betweenbaseline and last visit, differences were most pronounced
in the TACE plus Sorafenib group.
Liver transplantation
Due to the design of the trial, additional information on
LT has been obtained when the trial was finished. In total,
transplantation was performed in seventeen patients who
were actively involved in the trial at time of the surgery
and had no evidence of disease progression. In sixteen
of the patients, LT was performed in a modified Piggy-
back technique with organs from cadaveric donors [6].
One patient underwent an extended, right-lobe trans-
plantation using a graft from a cadaveric donor. LT was
performed in five patients (22.7%) from the Sorafenib
group and in twelve patients (46.2%) from the placebo
group. The median TTLT was 153 days in the Sorafenib
group (range: 31 to 339 days) and 174 days (range: 37
to 315 days) in the placebo group (Hazard Ratio: 0.575,
95% CI: 0.192, 1.721) (Figure 4).
The median operative times, blood loss and length of
the participants’ hospital stay were similar in patients from
the Sorafenib group and patients from the placebo group
(p = 0.02; p = 0.25 and p = 0.98). The overall 30-day mor-
bidity rate was 35%. Surgical re-intervention was neces-
sary in two patients from the placebo group due to the
Table 1 Baseline characteristics of study patients
TACE + Sorafenib TACE + Placebo
n = 24 n = 26
Age (years) median (min-max) 58.5 (44.0-66.0) 58.0 (43.0-69.0)
BMI (kg/m2) median (min-max) 27.5 (20.2-40.6) 26.3 (21.0-37.9)
Biopsy proven n (%)
yes 8 (33.3%) 6 (23.1%)
no 16 (66.7%) 20 (76.9%)
Child pugh stage n (%)
A 14 (58.3%) 20 (76.9%)
B 9 (37.5%) 6 (23.1%)
C 1 (4.2%) -
Karnofsky index n (%)
80 6 (25.0%) 4 (15.4%)
90 10 (41.6%) 16 (61.5%)
100 8 (33.3%) 6 (23.1%)
Underlying liver disease n (%)
Viral hepatitis
B 3 (12.5%) 3 (11.5%)
C 11 (45.8%) 7 (26.9%)
alcoholic 7 (29.1%) 11 (42.3%)
other 3 (12.5%) 5 (19.2%)
MELD score at listing
median (min-max)
labMELD score 11 (6–15) 11 (6–37)
exceptional MELD score 27.5 (27.5-40.1) 25.2 (21.9-40.1)
AFP (IU/ml) median (min-max)
start of study 13.2 (1.2 – 2.961) 9.8 (1.3 – 225)
end of study 6.2 (1.0 – 1.788) 9.4 (2.0 – 362)
Table 2 Treatment related adverse events classified
according to CTC-AEv3.0 Frequencies and 95% (two-sided)
confidence intervals according to Pearson-Clopper
TACE + Sorafenib TACE + Placebo
N = 24 N = 25
n % 95% CI n % 95% CI
Patients with at least one
AE
22 91.7 73.0 - 99.0 21 84.0 63.9 - 95.5
Blood/lymphatic disorders
ucopenia 10 41.7 22.1 - 63.4 3 12.0 2.5 - 31.2
thrombocytopenia 13 54.2 32.8 - 74.4 14 56.0 34.9 - 75.6
Gastrointestinal disorders
diarrhoea 9 37.5 18.8 - 59.4 3 12.0 2.5 - 31.2
nausea 3 12.5 2.7 - 32.4 2 8.0 1.0 - 26.0
General disorders
fatigue 5 20.8 7.1 - 42.2 5 20.8 6.8 - 40.7
weight loss 1 4.2 0.1 - 21.1 -
Hepatobiliary disorders
hyperbilirubinaemia 3 12.5 2.7 - 32.4 3 12.0 2.5 - 31.2
cholangitis 1 4.2 0.1 - 21.1 -
Dermatologic disorders
hand-foot-syndrome 7 29.2 12.6 - 51.1 1 4.0 0.1 - 20.4
alopecia 1 4.2 0.1 - 21.1 -
Sever AE 12 50.0 29.1 - 70.9 4 16.0 4.5 - 36.1
SAE (CTC-AEv3.0 GRADE 3/
4)
3 12.5 2.7 - 32.4 3 12.5 2.5 - 31.2
Study Drug discontinued
due to AE
6 25.0 9.8 - 46.7 1 4.0 0.1 - 20.4
Dose reduced due to AE 6 25.0 9.8 - 46.7 2 8.0 1.0 - 26.0
AE resulting in death - -
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duct leakage in the other. ERC due to bile duct stenosis
was necessary in two patients (one from each group).
Radiological re-intervention was necessary in two patients
(n = 1 from the Sorafenib group which was caused by
coiling of the splenic artery due to steal phenomenon and
n = 1 from the placebo group due to an infected bilioma).
No complications of delayed wound-healing, bowel dehis-
cence, or incisional hernia were observed in the Sorafenib
group. Acute rejection (Banff score 3 to 7) occurred in
three patients (n = 1 from the Sorafenib group and n = 2
from the placebo group).
Nine patients remained alive after a median follow-up of
320 days. One patient from the placebo group died within
30 days after LT due to cardiac decompensating. A total of
five patients died during the follow-up period (n = 1 from
cerebral oedema at four months after LT, n = 1 from myo-
cardial infarction, n = 1 from sepsis after colonic ischemia
at six months after LT, n = 1 from general sepsis, and n = 1from multiple organ failure at 24 months after LT). Re-
transplantation was performed in two patients (n = 1
was performed 23 days after LT and was due to primary
non-function; n = 1 was performed three days after LT and
was due to acute graft ischemia). Two transplanted pa-
tients who had been treated with the placebo experienced
recurrence of the disease with pulmonary metastases
within the first year of LT and subsequently died. Cur-
rently, there are no signs of recurrence in all other patients
still alive after LT.
Discussion
Without potentially curative liver transplantation, hepa-
tocellular carcinoma has a dismal prognosis. The concept
of locoregional treatment for bridging while awaiting LT
has been proven to be effective within the last decade and
excellent outcomes have been reported for the TACE
treatment option [26,27]. A meta-analysis clearly showed
the beneficial survival effect of TACE in comparison to
the results obtained from untreated cases [28]. In recent
Figure 2 Estimated Cumulative Incidence Functions for the Time-to-Progression for the two treatment groups.
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mal therapeutic regimen of transarterial chemoemboliza-
tion. Most centers now use drug eluting beads for their
TACE procedures and doxorubicin as chemotherapeutic
drug [29].
However, the effectiveness of TACE is hampered by
tumour progression during the waiting time and subse-
quent drop-out rates of up to 53% [30,31]. Recent evi-
dence suggests that neo-angiogenic reactions are induced
after TACE, which in turn, potentially enhances the
tumour growth of untreated nodules or accelerates the de-
velopment of de-novo tumours within the cirrhotic liver
[10]. Furthermore, a high increment of VEGF after TACE
has been recently identified as an independent, negativeFigure 3 Estimated Cumulative Incidence Functions for the Progression-freprognostic factor for both the progression-free and overall
survival rates [32,33]. Sorafenib has direct inhibitory ef-
fects on angiogenesis and cell proliferation in HCC; and in
two large, Phase III, randomized, controlled trials with
demographically different study populations of patients
with advanced HCC, Sorafenib has been shown to signifi-
cantly improve the time to progression [12,34]. The Hei-
LivCa trial was designed to capture the potentially
beneficial effects of a combined locoregional and systemic,
molecular-targeted treatment course for HCC patients
awaiting LT. The TTP was selected as the primary end-
point of the study because it is an efficient means of moni-
toring the effects associated with the stabilization of the
disease for a clinically relevant period of time.e Survival Rate for the two treatment groups.
Figure 4 Estimated Cumulative Incidence Functions for the Time-to-liver transplantation for the two treatment groups.
Hoffmann et al. BMC Cancer  (2015) 15:392 Page 8 of 11Previously, the use of Sorafenib in a post-transplantation
setting was controversially discussed because of its toxicity.
This was especially true when the occurrence of Grade III -
IV adverse events in the majority of patients ultimately
resulted in permanent dose reduction or treatment discon-
tinuation [35-37]. However, the overall experience with So-
rafenib in HCC patients awaiting LT is actually even
bleaker. Concerns regarding the potential negative side ef-
fects of Sorafenib have been raised [17,18,38-40]. Neverthe-
less, the performance of the trial was encouraged by
emerging reports about a near absence of liver toxicity or
treatment-related deaths [12,34].
There are three points that are of major interest when
discussing a neo-adjuvant Sorafenib treatment course be-
fore LT. The first is the safety when it is used in combin-
ation with locoregional treatment options. Data from
studies that investigated the combined use of TACE and
Sorafenib in patients with advanced HCC suggests that this
treatment option has an acceptable safety profile [41]. In
the HeiLivCa trial, 92% of patients in the Sorafenib group
experienced at least one treatment-related adverse event.
Of those, grade III or IV adverse events occurred in 50% of
patients. The major side effects observed in this study were
consistent with those reported in two previously conducted
randomised controlled trials and a pooled safety analysis of
a Sorafenib monotherapy trial for patients with advanced
HCC [12,34,42]. The most frequent adverse events in our
trial were thrombocytopenia, diarrhea, and hand-foot-skin
reactions, however, these events occurred less frequently in
comparison to the safety reports from previous Sorafenib
monotherapy trials. Furthermore, despite overlapping co-
morbidities in Child-Pugh class B patients, the treatment
was equally well tolerated in Child-Pugh class A and Bpatients. In this trial, only 24% of patients in the Sorafenib
group had dose reductions or temporary discontinuations
due to treatment-related adverse events; a figure that is sig-
nificantly lower than those values reported in other trials
[17,18]. The occurrence of fewer dose adjustments in more
recent trials could be attributed to the fact that physicians
have gained more experience in handling molecular-tar-
geted therapies, adverse events are monitored more aggres-
sively, and the management strategies for side effects have
been optimised over time [43]. There has been growing
concern about the increasing numbers of TACE-associated
complications when the therapy is used in combination
with an anti-angiogenic drug. In light of this, we decided to
interrupt drug treatment three days before and after each
TACE for this study. As a result of this strategy, no TACE-
associated or bleeding complications were observed.
The second point of interest on this topic is the effect of
Sorafenib on tumour growth during the waiting time. In
this study, the TTP remained constant with the combined
TACE plus Sorafenib therapy and the median TTP was
similar in both treatment groups. However, TTP has pre-
viously been challenged as a surrogate endpoint in trials
for advanced HCC because of the inconsistencies between
the OS and the TTP that have been detected in other
studies. ORR is currently being revisited as an alternative
endpoint after the introduction of modified RECIST as-
sessment in HCC. In our trial, the ORR and the Disease
Control Rate were also comparable in groups. Truesdale
et al. reported that there were no dropouts due to disease
progression in the Sorafenib group of their study [17].
Kulik et al. reported the occurrence of disease progression
during the trial in one patient under Sorafenib and one
patient of the control group [40]. Frenette et al. gave no
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ever, this could have been influenced by the fact that both
their study setting was different and that 93% of their
patients were beyond the MILAN criteria [18]. Neverthe-
less, all three groups reported that Sorafenib had no gen-
eral impact on overall survival rates after LT [17,18,40]. A
potential explanation for a failure of Sorafenib treatment
lies within the individual tumor biology of each patient.
HCC can be seen as a prototypical therapy-resistant
tumour [44-46]. Most recently analysis of therapy-naïve
HCC tissue has shown that baseline tissue expression of
pERK and VEGFR-2, both key molecules in the cancero-
genic pathway of HCCs, is inversely correlated with the
clinical outcome in advanced HCCs treated with Sorafenib
[47]. Furthermore, a pooled shRNA screen conducted to
identify target genes whose inhibition increases the thera-
peutic efficacy of Sorafenib identified MAPK14-dependent
activation as a key mechanism of Sorafenib resistance in
mouse and human liver cancer [48]. However, the inci-
dence of severe adverse events in the Sorafenib treated
patients and the combination with the lack of an impact on
the study end-points discourage in our view the use of the
drug in combination with TACE.
Lastly, the interaction of Sorafenib with the transplant-
ation setting is of particular interest for transplant surgeons.
Previous research with molecular-targeted therapies in a
pre-operative setting has raised concerns about the risk of
wound-healing complications, haemorrhage, and cardiac
events. The current study did not identify an overall in-
creased risk of delayed wound-healing, bowel perforation,
or incisional hernia. The intraoperative blood loss was not
higher in the Sorafenib group and this was in line with the
data from Frenette’s research [18]. On the other hand, Kulik
et al. and Truesdale et al. described both a potentially in-
creased risk for biliary complications and a higher rate of
rejection after neo-adjuvant Sorafenib use [17, 40]. How-
ever, the survival rates of two aforementioned trials were
the same in both the Sorafenib and the placebo groups.
We are well aware of the limitations of the present study.
To our knowledge, this is the largest cohort reported to
date. This study was designed under the assumption that
Sorafenib provides a 40% reduction in the hazard ratio for
TTP. However, the results showed no treatment difference
between Sorafenib and placebo. The observed hazard ratio
in TTP for Sorafenib compared to placebo was 1.106, 95%
CI of 0.387 to 3.162, indicating a slight disadvantage for So-
rafenib. Based on the data shown above, we calculated the
conditional power according to Andersen [49]. Even if the
accrual would be extended for another four years the con-
ditional power (based on the initial assumptions regarding
treatment effect) would be less than 10%. Consequently, we
stopped the study due to futility. With that being said, we
opted to report the results of the fifty patients treated in the
trial because of the clinical relevance. Due to the lowpatient numbers, any confirmatory statistical analysis was
unattainable inappropriate, therefore, the statistical analysis
that was actually performed was in a strictly exploratory
and mainly descriptive manner. It should also be empha-
sized that it is highly probable that a type 2 error, because
of the small sample size, would make the differences in
complications after LT difficult to detect.
Conclusion
In conclusion, we believe that this trial gives no evidence
on the indication of Sorafenib for HCC before LT. The
Time-to-Progression, the Objective Response Rates, and
the Disease Control Rates remained similar after the ad-
ministration of the combined neo-adjuvant treatment with
TACE and Sorafenib to HCC patients in our trial setting. In
combination with the increased incidence of adverse events
a recommendation for neo-adjuvant treatment with Sorafe-
nib and TACE cannot be given.
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